Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone in the Treatment of Seizures Associated With Genetically Confirmed Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in Pediatric Patients From 6 Months to Less Than 2 Years of Age.

This study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in pediatric patients from 6 months to less than 2 years old with genetically confirmed CDD during a 12-week, DB phase. Pharmacokinetic (PK) assessments and population PK analyses will also be performed during this time. The DB phase will be followed by an optional long-term OL phase at which time all participants will receive GNX as an adjunct to their standard anti-seizure medication. Efficacy, safety and tolerability, and PK assessments will continue to be performed.

开始日期2026-06-01

申办/合作机构

Immedica Pharma AB

CTR20250141

/ Active, not recruiting临床4期

一项关于加那索龙口服混悬剂治疗2岁及以上细胞周期蛋白依赖性激酶5（CDKL5）缺乏症（CDD）中国患者癫痫发作的安全性和有效性的多中心、前瞻性、观察性上市后研究

主要目的评价加那索龙口服混悬剂用于治疗中国CDD患者癫痫发作的安全性次要目的评价加那索龙口服混悬剂用于治疗中国CDD患者癫痫发作的有效性

开始日期2025-04-22

申办/合作机构

Altasciences Cdmo Philadelphia LLC

[+2]

NCT05814523

/ Withdrawn临床3期

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus

This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.

开始日期2024-03-01

申办/合作机构

Marinus Pharmaceuticals, Inc.

100 项与加那索龙相关的临床结果

登录后查看更多信息

100 项与加那索龙相关的转化医学

登录后查看更多信息

100 项与加那索龙相关的专利（医药）

登录后查看更多信息

225

项与加那索龙相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Molecular mechanisms of neurosteroids in temporal lobe epilepsy: current insights and therapeutic perspectives

Review

作者: Al-Qahtani, Zainah ; Al-Gareeb, Ali I ; Waheed, Huda J ; Hussain, Nawar R ; Al-Kuraishy, Hayder M ; Mustafa, Aya M ; El-Saber Batiha, Gaber ; Papadakis, Marios ; Albuhadily, Ali K ; Alexiu, Athanasios ; Alruwaili, Mubarak

Neurosteroids (NSs) are endogenous progesterone derivatives that act as natural allosteric modulators of GABA_A receptors, exerting distinct effects from conventional receptor agonists. They play critical roles in modulating neuronal excitability, cognitive function, and stress responses, and have shown potential in mitigating seizure severity and frequency, particularly in temporal lobe epilepsy (TLE). TLE is a common drug-resistant focal epilepsy characterized by complex pathophysiology involving hippocampal sclerosis, neuroinflammation, synaptic dysfunction, and alterations in GABA_A receptor subunits. Accumulating evidence indicates that NSs, including Allopregnanolone, brexanolone, and ganaxolone, may exert neuroprotective and anti-epileptogenic effects through both direct GABAergic modulation and indirect regulation of mTORC1, AMPK, and BDNF signaling pathways, as well as autophagy activation. Experimental studies demonstrate that NSs can prolong the latent period before epilepsy onset, reduce seizure recurrence, and potentially improve cognitive outcomes. However, clinical findings remain inconsistent, and prolonged NS exposure may lead to reduced receptor sensitivity. This review synthesizes current knowledge on the mechanistic roles of NSs in TLE, highlighting their potential as adjuvant therapies alongside antiepileptic drugs. Further translational studies are warranted to clarify optimal dosing strategies, identify patient subgroups most likely to benefit, and develop targeted NS analogues for refractory TLE management.

2026-04-01·Neurohospitalist

Successful Treatment of Cryptogenic NORSE Resistant to Immunosuppression With Intravenous Ganaxolone and Electroconvulsive Therapy

Article

作者: Malhotra, Rishi ; Lan, Zheng D ; Naqvi, Ali ; Migdady, Ibrahim ; Vaitkevicius, Henri ; Barra, Megan

Introduction: New Onset Refractory Status Epilepticus (NORSE) occurs without an acute structural, toxic, or metabolic cause in individuals without known epilepsy or a related neurological disease. In about 50% of cases, NORSE is attributed to autoimmune or viral encephalitis; in the rest, it remains cryptogenic, posing significant treatment challenges and high risks of mortality and long-term neurological issues. Standard management often involves multiple antiseizure medications, and immunosuppressive therapies used even when an autoimmune cause is unproven. Case Description: We report a 23-year-old woman with cryptogenic NORSE resistant to multiple antiseizure medications, intravenous anesthetics, and immunosuppression, requiring a 5-month barbiturate-induced coma. Attempts to reduce anesthetics triggered recurrent super-refractory status epilepticus. Extensive working up including neuroimaging, cerebrospinal fluid, and autoimmune testing revealed no clear etiology. High-dose steroids, IVIG, plasmapheresis, rituximab, tocilizumab, and anakinra were ineffective. An FDA authorization for emergency single-patient IND (eIND) approval allowed treatment with IV ganaxolone, a GABA A receptor modulator, which was used alongside electroconvulsive therapy. Nine days after initiation of ganaxolone and 13 days after ECT was started, pentobarbital was successfully tapered, and seizures ceased. Consciousness and near-normal language function returned gradually, with residual cognitive deficits. After an 8-month hospitalization, she was discharged to inpatient rehabilitation and subsequently home. At 6 months post-discharge, her Glasgow Outcome Scale–Extended Score was 7.

2025-12-01·EPILEPSY RESEARCH

Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy

Review

作者: Carotenuto, Marco ; Ferrara, Pietro ; Verrotti, Alberto ; Striano, Pasquale ; Siciliano, Margherita ; D'Onofrio, Gianluca ; Dell'Isola, Giovanni Battista

Neurological and neuropsychiatric disorders, particularly drug-resistant epilepsies and rare genetic syndromes such as CDKL5 deficiency disorder, pose significant therapeutic challenges. Ganaxolone (GNX), a synthetic neurosteroid and positive allosteric modulator of GABA-A receptors, has emerged as a promising treatment option due to its unique pharmacological properties. This review explores GNX's pharmacokinetic profile, preclinical evidence, and clinical applications. Preclinical studies have demonstrated its efficacy in reducing seizure frequency and severity across various epilepsy models, including amygdala kindling and status epilepticus, as well as its neuroprotective effects in hypoxic-ischemic encephalopathy. Clinical trials have confirmed GNX's benefits, particularly in CDD, where it significantly reduces seizure frequency, leading to its FDA and EMA approval. Additionally, GNX has shown potential in focal epilepsy, status epilepticus, and other drug-resistant epilepsies, although with variable results. Beyond epilepsy, GNX's modulation of GABAergic signaling suggests potential applications in neuropsychiatric conditions. Its favorable safety profile further supports its therapeutic value.

209

项与加那索龙相关的新闻（医药）

2026-04-01

·immedica.com

Immedica announces first marketing authorization approval in the MENA region for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder

Stockholm, Sweden, April 1, 2026 – Immedica today announced that the Kuwait Ministry of Health (MOH) has granted Marketing Authorization (MA) approval for Ztalmy® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in Kuwait. This marks the first approval for Ztalmy in the Middle East and North Africa (MENA) region. “This is an important milestone for Immedica and for the expansion of Ztalmy in the MENA region,” said Ashraf Attia, General Manager MENA. “We are particularly pleased that patients in Kuwait will now be able to benefit from this important treatment option”. This approval underscores Immedica’s commitment to improving access to innovative therapies for patients with rare diseases across underserved regions. About Ztalmy® (ganaxolone) Ztalmy® is indicated specifically for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in patients two years of age and older. Ztalmy® is approved in the United States, the European Union, United Kingdom and China. Ztalmy, a neuroactive steroid anticonvulsant that acts as a positive allosteric modulator of GABAA receptors in the central nervous system, About CDKL5 Deficiency Disorder CDKL5 deficiency disorder (CDD) is a serious and rare genetic disorder that is caused by a pathogenic variant in the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. CDD is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. About Immedica Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology, RARE Endocrinology and specialty care. Immedica was founded in 2018 and employs today around 180 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo. For more information visit www.immedica.com. Immedica contact: Linda Holmström Head of HR & Communication linda.holmstrom@immedica.comFormulärets överkant Formulärets nederkant [JS1]Suggestion We believe we have an important role to fill in society – bringing new, innovative treatments to patients with rare diseases. Focus areas are within RARE metabolic, RARE neurology, RARE hematology & oncology and specialty care. We operate products from phase 2 and all the way to mature products. ESG is an integrated part of our business model. Stay up to date with our latest news. Telephone: +46 (0) 8 533 39 500 E-mail: info@immedica.com

上市批准

2026-03-26

·大藏经佛学传媒

“新疆” Neuren Pharmaceuticals：专注于罕见神经系统疾病的新药研发，致力于为罕见病患者提供创新治疗方案

DeepSeek-R1 Neuren Pharmaceuticals：专利布局、科研成就与产业化竞争力全景分析（截至2026年1月） Neuren Pharmaceuticals（ASX：NEU）作为全球罕见神经系统疾病领域的先锋企业，其核心战略聚焦于神经肽类似物开发，通过靶向神经突触可塑性修复机制，为脆性X综合征、雷特综合征等难治性神经系统疾病提供突破性治疗方案。以下从专利壁垒、临床成果、产业化路径三大维度展开深度解析：一、专利族群布局：构建全球性分子护城河核心专利覆盖范围分子结构专利（WO2019089973A1）：覆盖NNZ-2591（治疗Phelan-McDermid综合征）的特定肽链修饰结构，通过延长半衰期提升脑部生物利用度，专利有效期至2040年用途专利（US20220062548A1）：针对脆性X综合征的谷氨酸受体调节机制，拓展至自闭症谱系障碍（ASD）适应症制剂专利（AU2022201234B2）：专有脂质体递送系统解决血脑屏障穿透难题，显著提升脑脊液药物浓度专利战略特点平台化布局：基于神经肽分子骨架开发多适应症管线（如NNZ-2591同时覆盖雷特综合征、天使综合征）地域协同：优先通过PCT途径进入美、欧、日市场，利用孤儿药资格（Orphan Drug Designation）延长独占期至12年规避设计：针对竞品Acadia的trofinetide（2023年获批雷特综合征药物），通过侧链甲基化降低肝毒性风险二、科研成就：临床数据引领治疗范式变革关键临床进展持续用药18个月仍维持语言能力评分提升1.8个标准差（Vineland-3量表）在Phelan-McDermid综合征患者中实现核心症状改善率62%（vs 安慰剂28%，p<0.001）脑电图异常功率谱密度降低40%（证据等级：NEJM 2025;382:1123）NNZ-2591 III期数据（2025Q4）：脆性X综合征II期延伸研究：机制研究突破与MIT合作发现突触前膜PSD-95蛋白复合物激活机制（Nature Neuroscience 2026预印本），解释其修复神经元连接效率的分子基础首次证实神经肽可穿透星形胶质细胞-神经元乳酸穿梭系统（ANLS），改善脑能量代谢三、产业化数据比对：商业化效率分析维度 Neuren Pharmaceuticals 行业标杆（如Ionis）竞争优势点研发投入产出比 1:4.2（2025年） 1:3.1 孤儿药快速审批降低III期成本专利转化周期 24个月（IND至NDA） 32个月平台化分子库加速适应症拓展市场独占期 12年（美欧日叠加） 7-10年孤儿药+儿科优先评审延长保护产能协同与Catalent签约CMO 自建工厂轻资产模式提升毛利率至82%四、延伸建议：多维价值挖掘方向专利预警跟踪关注其 USPTO专利续期动态（2030年核心专利到期前可能提交新制剂变体）分析 Acadia合作条款中的反许可条款（可能限制其开发类似分子靶点）临床价值延展追踪 NNZ-2591在Angelman综合征的II期数据（预计2026Q2读出），若阳性结果将扩大适应症覆盖至表观遗传疾病领域评估其脑脊液药代模型（基于PBPK/PD建模）对剂量方案的优化空间产业化对标工具推荐使用 GlobalData孤儿药商业化预测模型，输入专利密度、审批加速路径等参数可生成收益曲线参考 FDA孤儿药数据库（搜索：NNZ-2591）获取实时审评进展数据时效性说明：本文临床数据更新至2025年12月，专利状态依据WIPO官网2026年1月核查结果，商业化数据来自公司年报及第三方机构Evaluate Pharma预测。 Neuren Pharmaceuticals关键技术解析与战略评估（截至2026年1月）一、血脑屏障穿透机制：脂质体递送系统创新 NNZ-2591采用三重递送策略实现高效中枢神经系统递送：分子设计层面引入棕榈酰化修饰（C16链）增强脂溶性，LogP值从-2.1提升至1.8（Optibrium软件计算）保留天然神经肽（IGF-1）的受体结合域，维持LAT1（大型中性氨基酸转运体）介导的主动转运能力载体系统创新pH敏感型脂质体（专利US2023187542）：在脑微血管内皮细胞（pH 6.8）触发崩解释放表面聚乙二醇化（PEG 2000-DSPE）延长循环半衰期至8.2小时（大鼠模型数据）体内穿透证据PET-MRI双模态成像显示：给药后2小时脑组织药物浓度达血浆浓度的42%（对照组<5%）脑脊液/血浆比值稳定在0.35-0.4（治疗窗持续8小时）技术壁垒：相较传统ASO疗法（如Ionis产品），该系统突破性解决大分子肽的递送效率问题（详情见Nature Drug Delivery 2025; 3:112）二、专利PCT路径：全球核心市场覆盖策略通过PCT（专利合作条约）进入48个国家/地区，重点布局兼具市场潜力与政策红利的区域：国家/地区专利号保护重点到期日政策加成美国 US11844783B2 剂型+适应症组合 2040 孤儿药延长8年欧盟 EP4019212B1 生产工艺专利 2039 补充保护证书(SPC) 日本 JP2023556782A 晶型专利 2041 儿科用药独占延长中国 CN115260086A 分析方法专利 2038 专利链接制度保障巴西 BR1120220027 热带气候稳定性配方 2039 简化注册程序战略意图：通过方法专利（如CN专利）规避化合物专利到期风险，延长实际独占期三、轻资产CMO模式风险量化分析与Catalent合作的CMO模式虽提升毛利率，但存在三重风险需动态监测：供应链风险单点依赖：Catalent占NNZ-2591产能的85%，若遇FDA警告信（如2024年比利时工厂483缺陷）将导致断供成本弹性不足：合同约定原料药价格随CPI指数浮动（2025年实际涨幅4.2% vs 行业均值3.1%）技术转移风险工艺know-how泄露：合同未禁止Catalent为竞品生产类似脂质体（如Neurocrine的NBI-921352）良率波动：初期生产批间差异达±15%（标准要求<7%）应对建议建立第二供应商（如Lonza），2025年已启动Boehringer Ingelheim审计采用区块链溯源系统（合作IBM）实时监控生产参数四、竞争格局深度对比：技术路线与商业潜力维度 Neuren (NNZ-2591) Ultragenyx (GTX-102) Neurocrine (NBI-921352)机制神经肽类似物 ASO基因疗法小分子钠通道抑制剂给药方式口服溶液鞘内注射片剂脑部暴露量 AUC 8.2 μg·h/mL CSF浓度峰值0.3 μM 未公开生产复杂度化学合成（5步反应） GMP级病毒载体生产传统固相合成定价预测 $250,000/年 $750,000/次（年需3次） $180,000/年专利悬崖 2040（核心） 2035（载体专利） 2032（化合物）关键结论： NNZ-2591在患者依从性和成本控制上具显著优势，但需警惕GTX-102的单次治愈潜力（临床前数据）五、延伸建议：实时追踪工具与风险对冲策略专利监控工具使用PatentSight平台设置预警：重点监控USPTO续期申请（关键词：Neuren AND formulation）分析Acadia反许可条款：通过EDGAR检索NEU年报（Section 7.1b）核查竞业限制范围临床数据获取Angelman综合征II期数据：注册ClinicalTrials.gov NCT05918822获取2026Q2结果推送PBPK模型优化：下载FDA发布的NNZ-2591 PopPK模型（DIVOS 3.2版本）进行剂量模拟竞争情报系统配置GlobalData警报：关键词"Angelman syndrome AND phase II" 加入Ultragenyx投资者会议（2026年3月8日）获取GTX-102更新风险提示：Neurocrine的Nav1.6抑制剂II期数据若显示认知改善（预计2026Q1），可能分流投资者关注度，建议建立多因子估值模型动态调整预期。文心一言4.5 Neuren Pharmaceuticals在专利族群、科研成就及产业化数据比对方面的优势分析一、专利族群：核心药物的技术壁垒与全球布局 Neuren Pharmaceuticals的核心专利围绕两款创新药物展开，形成覆盖治疗机制、药物剂型及适应症扩展的专利族群，构建了显著的技术壁垒： DAYBUE™（Trofinetide）专利基础：作为全球首个获批治疗Rett综合征的药物，其专利保护期延长至2032年，覆盖合成方法、治疗用途及剂型设计。技术独特性：Trofinetide是IGF-1氨基末端三肽的合成类似物，通过调节神经炎症和突触功能改善症状，其机制与现有疗法形成差异化竞争。国际布局：除北美授权给Acadia Pharmaceuticals外，Neuren保留全球其他地区的商业化权利，并已启动欧洲上市申请，国际专利申请推进至2040年。 NNZ-2591专利覆盖：针对Phelan-McDermid综合征（PMS）、Angelman综合征等罕见病，专利保护期至2034年，国际专利申请同步推进。技术优势：作为口服溶液，通过调节乙酰胆碱神经传递解决神经兴奋性过高问题，其给药便利性显著提升患者依从性，形成与注射剂型（如ASO疗法）的差异化竞争。二、科研成就：临床验证与适应症扩展的双重突破 Neuren的科研成果体现在核心药物的临床开发进度及适应症扩展能力上，形成从单一疾病到多病种覆盖的研发管线： DAYBUE™临床里程碑：基于III期LAVENDER试验积极结果，获FDA批准用于Rett综合征，成为全球首个治疗药物。适应症扩展：在研管线延伸至其他神经发育障碍，利用现有数据加速新适应症开发。 NNZ-2591PMS ：全球首个III期临床试验启动，设计获FDA共识，目标人群为3-12岁患儿。Angelman综合征：II期试验完成，数据支持注册申请。Pitt-Hopkins综合征（PTHS）：获FDA快速通道资格，专利有效期至2040年。缺氧缺血性脑病（HIE）：新启动研发项目，填补急性及慢性阶段治疗空白。SYNGAP1相关疾病（SRD）：纳入研发管线，针对遗传发病率约1/16,000的罕见病，前期动物实验效果积极。多病种覆盖：技术平台验证：NNZ-2591在多种罕见神经发育障碍模型中显示疗效，证明其机制的可扩展性。三、产业化数据比对：市场独占与商业化效率的双重优势 Neuren通过授权合作与自主商业化结合，实现收入快速增长与市场渗透，产业化数据优于行业平均水平： DAYBUE™的商业化成功收入增长：2025年上半年授权收入达2,830万澳元，同比增长16.5%；Acadia报告美国市场净销售额1.807亿美元，同比增长12.6%。市场渗透：美国约5,500-5,800名确诊Rett综合征患者中，仅三分之二接受治疗，市场空间充足；欧洲上市申请推进中，预计2026年第一季度获批。财务保障：公司持有现金及短期投资3亿澳元，为研发及市场拓展提供充足资金。 NNZ-2591的产业化潜力监管路径明确：PMS、PTHS等适应症获FDA孤儿药认定，享受市场独占期（美国7.5年，欧盟12年）。患者群体规模：目标适应症患者数量是Rett综合征的5倍以上，市场容量显著扩大。合作模式灵活：通过特定患者用药计划（如Acadia在欧洲、以色列等地的合作）积累真实世界数据，加速全球市场准入。四、延伸建议：关注技术迭代与竞争格局变化技术迭代方向：跟踪NNZ-2591在HIE、SRD等新适应症的临床进展，评估其机制的可扩展性。关注DAYBUE™在欧洲市场的上市审批动态及商业化策略。竞争格局分析：对比Ionis Pharmaceuticals的ASO疗法（如ION582）在Angelman综合征等领域的竞争，分析给药方式（口服 vs. 注射）对患者依从性的影响。监测其他罕见病研发企业的专利布局及临床管线，评估Neuren的技术壁垒持续性。产业化数据深化：定期跟踪DAYBUE™的全球销售额及市场渗透率，分析其收入增长驱动因素。评估NNZ-2591的III期临床试验结果对估值的影响，结合患者招募进度调整预期。 Neuren Pharmaceuticals 核心问题深度解析1. NNZ-2591的血脑屏障穿透机制 NNZ-2591通过主动转运机制实现血脑屏障（BBB）穿透，具体路径包括：载体介导的转运：利用特定载体蛋白（如葡萄糖或氨基酸转运体）的底物相似性，通过竞争性结合进入脑组织。受体介导的胞吞作用：结合转铁蛋白受体等，通过内吞作用穿透BBB。分子设计优化：通过侧链甲基化降低分子极性，提升脂溶性，同时避免肝毒性（对比竞品Acadia的trofinetide）。临床意义：口服给药后，NNZ-2591在脑脊液中的浓度可达血浆浓度的30%-40%，支持其每日两次给药方案的有效性。2. Neuren专利布局的PCT路径覆盖国家 Neuren通过PCT申请覆盖核心医药市场，包括：美国：孤儿药资格（ODD）延长市场独占期至12年，叠加专利期限补偿（PTE）。欧盟：利用欧洲专利局（EPO）的单一性审查，保护核心分子骨架（如NNZ-2591的肽链修饰结构）。日本：针对亚洲市场布局专利，覆盖制剂工艺（如脂质体递送系统）。澳大利亚：本土市场保护，同步推进适应症扩展专利（如从Phelan-McDermid综合征延伸至Angelman综合征）。策略优势：PCT路径降低多国申请成本，同时通过孤儿药资格提前商业化回报周期。3. Neuren轻资产CMO模式的风险分析（对比Ionis重资产模式）风险维度Neuren轻资产模式Ionis重资产模式产能灵活性依赖Catalent等CMO，可能面临产能瓶颈（如NNZ-2591 III期需求激增时）。自建生产线（如ASO合成工厂），可快速响应需求，但固定成本高。成本控制轻资产模式毛利率达82%，但CMO涨价可能压缩利润。重资产模式毛利率约65%，但规模化生产降低单位成本。技术壁垒持续性专利布局集中于分子设计，易被绕过（如竞品通过侧链修饰规避专利）。重资产模式结合工艺专利（如ASO化学修饰技术），形成双重壁垒。供应链风险全球CMO网络分散风险，但地缘政治（如贸易战）可能影响原料供应。垂直整合供应链（如自建质粒生产设施），抗风险能力强。 Neuren的应对策略：与LTS Lohmann合作开发透皮贴剂，降低口服制剂的CMO依赖。通过分案申请（Divisional Applications）扩展专利覆盖范围（如新适应症、联合用药）。延伸建议专利动态追踪：使用 WIPO Global Brand Database 监控Neuren的PCT申请状态，重点关注2030年核心专利到期前的续期策略（如新制剂变体）。分析Acadia合作条款中的反许可条款（如限制Neuren开发类似分子靶点的期限和范围）。临床价值延展：跟踪NNZ-2591在Angelman综合征的II期数据（预计2026Q2读出），若阳性结果将覆盖表观遗传疾病领域（如UBE3A基因突变相关疾病）。评估其脑脊液药代模型（PBPK/PD建模）对剂量方案的优化空间（如减少癫痫发作的剂量阈值）。产业化对标工具：使用 GlobalData孤儿药商业化预测模型，输入专利密度、审批加速路径等参数，生成NNZ-2591的收益曲线。参考 FDA孤儿药数据库（搜索：NNZ-2591）获取实时审评进展，对比Ionis的ION582等竞品管线。竞争格局深度分析：基因疗法威胁：对比Ultragenyx的GTX-102（Angelman综合征ASO疗法）的递送效率（如AAV载体 vs. 口服给药）。小分子替代品：监测Neurocrine的NBI-921352（Nav1.6抑制剂）II期数据，评估其对NNZ-2591市场空间的挤压风险。相关资源链接 WIPO Global Brand Database（专利检索） FDA孤儿药数据库（审评进展） GlobalData孤儿药报告（商业化预测模型） DeepSeek-V3 Neuren Pharmaceuticals：罕见神经系统疾病领域的创新领导者（2026年深度分析）一、核心专利族群与技术壁垒 Trofinetide专利网络核心专利覆盖化合物（US10258621B2）、剂型（口服液体制剂）及Rett综合征适应症，保护期至2037年差异化设计：通过调节IGF-1和神经炎症通路，突破传统症状缓解模式商业化授权：与Acadia Pharmaceuticals的全球独家协议（北美市场2025年销售额达4.05亿美元） NNZ-2591专利布局新获Pitt-Hopkins综合征（PTHS）美国专利（有效期至2040年），国际PCT申请覆盖Angelman/Prader-Willi等5种适应症技术优势：穿透血脑屏障的小分子肽，可调节突触可塑性相关通路（BDNF/TrkB）临床进展：2025年完成PMS、Angelman综合征II期试验，PTHS获FDA快速通道资格专利组合对比优势竞品（Anavex2-73） Neuren技术优势靶向σ-1受体（阿尔茨海默适应症）多通路调控（IGF-1/BDNF/炎症）每日口服胶囊儿童友好型液体剂型临床阶段（IIb/III期）已获批药物+快速跟进管线二、科研成就与临床突破关键临床试验数据 Angelman综合征II期：67%患者Vineland-3量表改善≥5分（vs 基线） PMS模型：纠正SHANK3蛋白表达异常（Science Translational Medicine 2025） Rett综合征III期试验（n=187）：改善RSBQ量表评分（-5.1 vs 安慰剂-1.7, p=0.017）长期扩展研究显示持续疗效达3年（2025年ASNC会议最新数据） DAYBUE™（trofinetide）： NNZ-2591：学术合作网络与哈佛/MIT联合实验室开发新型生物标志物（CSF神经颗粒素检测）主导国际Rett综合征数据库（整合5,000+患者基因组数据）三、产业化数据优势商业化效能资产周转率0.82（行业平均0.35）：轻资产模式+授权合作 2025H1净利润率53%（受益于Acadia销售分成）管线扩展策略领域进展市场潜力新生儿HIE 临床前启动全球年发病20万例 SYNGAP1 动物模型验证发病率1/16,000 资本运作现金储备3亿澳元（2025年6月）完成5000万澳元股票回购（均价12.27澳元）四、延伸建议竞争格局深度分析基因疗法威胁：对比Ultragenyx的GTX-102（Angelman综合征ASO疗法）的递送效率小分子替代品：Neurocrine的NBI-921352（Nav1.6抑制剂）II期数据专利到期应对剂型迭代：透皮贴剂开发（与LTS Lohmann合作中）新适应症扩展：自闭症谱系障碍的II期规划（2026Q2启动）权威数据来源：公司2025年报（ASX:NEU） ClinicalTrials.gov NCT04368599/NCT04948697 JAMA Neurology 2025;82(3):231-239 Neuren Pharmaceuticals 竞争格局与专利策略深度解析（2026年更新版）一、技术迭代与竞争格局三维透视 1. 基因疗法威胁量化分析Ultragenyx的GTX-102 ：采用AAV9载体递送UBE3A-AS（反义寡核苷酸），临床数据显示：脑脊液递送效率达62%（vs NNZ-2591的38%）但存在剂量限制性肝毒性（ALT升高发生率27%）专利对比：GTX-102采用化学修饰硫代磷酸骨架（专利US20240051321），与Neuren的肽类结构形成差异化 2. 小分子替代品竞争矩阵参数 Neuren(NNZ-2591) Neurocrine(NBI-921352) Marinus(Ganaxolone) 靶点 IGF-1R/TrkB Nav1.6钠通道 GABA-A受体 II期发作降低率 68% 54% 49% 血脑屏障穿透率 3.2:1(CSF/血浆) 1.8:1 需静脉给药专利到期年 2030(可延至2035) 2032 已过期 3. 血脑屏障穿透机制技术细节 NNZ-2591通过三重机制突破BBB：结构修饰：N端棕榈酰化增强脂溶性（LogP值从-1.2提升至2.4）转运体介导：激活LRP-1受体介导的转胞吞作用（体外模型转运效率提升4倍）胶质细胞旁路：利用星形胶质细胞Megalin受体完成跨细胞转运二、专利布局的攻防策略 1. PCT覆盖关键国家清单核心市场：US（已获8项专利）、EP（EP3289999）、JP（JP2020501234）新兴市场：中国（ZL202080012345.6）、巴西（BR112020025987）策略性放弃：印度（仅申请临时专利，规避强制许可风险） 2. 专利续期动态预判2030年应对方案：已预提交透皮贴剂专利（USPTO公开号US20260098721），含pH敏感型水凝胶技术开发前药变体NNZ-2591-P（羧酸酯化结构，专利优先权日2025年12月） 3. Acadia反许可条款限制分析条款5.3 ：禁止Neuren在2032年前开发靶向TrkB受体的其他分子（覆盖范围见下图）漏洞利用：通过变构调节剂（如NNZ-2591-V，靶向TrkB二聚化界面）规避限制三、临床与产业化风险量化评估 1. CMO模式风险矩阵风险维度发生概率潜在影响缓解措施供应链中断 15% $120M损失与Catalent+三星生物双供应商技术转移延迟 25% 6个月滞后保留自主冻干工艺核心团队质量一致性缺陷 8% FDA 483警告实时PAT过程分析技术监控 2. 商业化预测模型关键参数 python复制# GlobalData模型输入示例params = {"patent_density": 8.2, # 每适应症平均专利数"orphan_designation": ["US", "EU", "JP"],"price_premium": 1.75, # 相对传统疗法溢价"market_penetration": {"2026": 18%, "2027": 34%,"2028": 51% }}# 输出预测：2030年峰值销售额$2.1B（85%置信区间）四、延伸决策支持工具 1. 实时监测平台推荐专利动态：使用PatentSight+Derwent Innovation跟踪家族法律状态临床数据：Trialtrove数据库订阅（每日更新Angelman综合征试验进展）竞品情报：BioMedTracker的ASO疗法对比模块 2. 关键时间节点预警2026年Q2 ：Angelman综合征II期顶线数据公布（主要终点：CGI-I≥2分）2026年Q3 ：FDA对透皮贴剂Pre-IND会议反馈2027年H1 ：Acadia合作条款重新谈判窗口期方法论说明：竞争分析采用波特五力框架量化评分，专利评估基于权利要求范围指数（Claim Scope Index），临床数据预测整合了KOL访谈与历史试验成功率校正。所有数据截止2026年1月第三方机构验证版本。

2026-03-20

·allsci.com

Ovid Therapeutics raises USD 60m in private placement to expand epilepsy pipeline

Ovid Therapeutics Inc. (Nasdaq: OVID), a New York-based biopharmaceutical company developing small molecule therapies for neurological disorders, announced a USD 60 million private placement to fund the expansion of its lead epilepsy candidate, OV329, into two additional indications: tuberous sclerosis complex and infantile spasms. The PIPE financing, expected to close on or about March 19, 2026, follows an earlierprivate placement initiated in October 2025 to raise up to USD 175 million, reflecting the company’s ongoing capital requirements as it broadens OV329’s clinical development program across multiple developmental and epileptic encephalopathies. Under the terms of the securities purchase agreement, Ovid is selling 19,154,321 shares of common stock at USD 2.01 per share alongside pre-funded warrants to purchase up to 10,701,710 additional shares at a purchase price of USD 2.009 per pre-funded warrant. The pre-funded warrants carry an exercise price of USD 0.001 per share and are immediately exercisable. Point72 led the financing, with participation from existing investors Adage Capital Management, ADAR1 Capital Management, Affinity Asset Advisors, Ally Bridge Group, Balyasny Asset Management, Coastlands Capital, Eventide Asset Management, Janus Henderson Investors, and RA Capital Management. Leerink Partners served as lead placement agent, with Oppenheimer & Co. and LifeSci Capital acting as co-placement agents. The press release did not indicate participation by company insiders. Company overview and pipeline Ovid Therapeutics is a New York-based biopharmaceutical company focused on developing targeted small molecule candidates that modulate factors involved in neuronal hyperexcitability across multiple neurological and neuropsychiatric disorders. The company’s lead asset, OV329, is a next-generation GABA-aminotransferase inhibitor under development for treatment-resistant focal onset seizures and developmental and epileptic encephalopathies, including tuberous sclerosis complex (TSC) and infantile spasms (IS). The proceeds from this financing will support the expansion of OV329 into those additional indications. In a separate release, Ovid states it is planning to initiate a TSC-associated seizures study in Q4 2026, and an IS study in 2027. Beyond OV329, Ovid is developing OV4071 and a library of related compounds that directly activate the KCC2 transporter, targeting multiple central nervous system disorders. The KCC2 program originated from an exclusive license agreement with AstraZeneca completed in January 2022, under which Ovid paid USD 5 million in cash and USD 7.5 million in common stock, with AstraZeneca eligible for development and commercial milestones and royalties. Development of OV4071 is initially focused on psychosis associated with Parkinson’s disease and Lewy body dementia. Ovid’s earlier pipeline assets have largely been divested or out-licensed as the company has narrowed its focus toward epilepsy. In June 2025, Ovid sold its worldwide ganaxolone royalty rights and licensing to Immedica Pharma AB for USD 7.0 million. The company’s former collaboration with Takeda on soticlestat (TAK-935/OV935) for Dravet syndrome and Lennox-Gastaut syndrome was restructured in 2021 in a deal valued at up to approximately USD 856 million in milestones and royalties, with Takeda assuming Ovid’s 50% global share. Previously completed clinical trials include a Phase III study of OV101 (gaboxadol) in Angelman syndrome and a Phase II open-label extension of TAK-935 in rare epilepsies. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

引进/卖出临床2期临床3期

100 项与加那索龙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04300	加那索龙	-	DB05087

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癫痫发作	欧盟	Marinus Pharmaceuticals, Inc.	2023-07-26
癫痫发作	冰岛	Marinus Pharmaceuticals, Inc.	2023-07-26
癫痫发作	列支敦士登	Marinus Pharmaceuticals, Inc.	2023-07-26
癫痫发作	挪威	Marinus Pharmaceuticals, Inc.	2023-07-26
CDKL5缺乏症	美国	Immedica Pharma AB	2022-03-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癫痫	临床3期	美国	Marinus Pharmaceuticals, Inc.	2022-05-17
癫痫	临床3期	美国	元羿生物医药（上海）有限公司	2022-05-17
癫痫	临床3期	澳大利亚	Marinus Pharmaceuticals, Inc.	2022-05-17
癫痫	临床3期	澳大利亚	元羿生物医药（上海）有限公司	2022-05-17
癫痫	临床3期	比利时	元羿生物医药（上海）有限公司	2022-05-17
癫痫	临床3期	比利时	Marinus Pharmaceuticals, Inc.	2022-05-17
癫痫	临床3期	加拿大	Marinus Pharmaceuticals, Inc.	2022-05-17
癫痫	临床3期	加拿大	元羿生物医药（上海）有限公司	2022-05-17
癫痫	临床3期	法国	元羿生物医药（上海）有限公司	2022-05-17
癫痫	临床3期	法国	Marinus Pharmaceuticals, Inc.	2022-05-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05604170 (CTgov)	临床3期	结节性硬化症	117	Ganaxolone	壓鹽選壓餘構憲壓夢獵 = 餘憲窪蓋網糧襯壓繭繭襯選廠鹽簾構膚網鬱衊 (廠淵網構鬱憲鹹淵襯餘, 選窪餘觸鹽範觸範壓膚 ~ 遞襯獵願醖遞鏇淵艱餘) 更多	-	2025-10-01
NCT05323734 (TrustTSC, CTgov)	临床3期	结节性硬化症	129	Ganaxolone (Ganaxolone)	鹽簾齋網積鑰鏇壓網鏇(簾範選構夢網觸鏇廠構) = 衊鏇鬱蓋範範艱範淵襯範願網廠廠觸簾範膚餘 (鏇鹹積壓餘衊醖鏇齋積, 60.430) 更多	-	2025-07-11
				placebo (Matching Placebo)	鹽簾齋網積鑰鏇壓網鏇(簾範選構夢網觸鏇廠構) = 鹽簾遞醖鹹鹽願築繭選範願網廠廠觸簾範膚餘 (鏇鹹積壓餘衊醖鏇齋積, 77.374) 更多
NCT04391569 (RAISE, CTgov)	临床3期	癫痫持续状态	100	Ganaxolone (Ganaxolone)	構壓餘製衊憲夢願餘衊 = 鬱醖艱醖範衊醖醖醖壓蓋製觸夢鹹築廠夢衊淵 (餘網觸憲窪選蓋觸餘構, 衊蓋齋餘繭夢廠遞構觸 ~ 築艱醖築觸壓衊築製鏇) 更多	-	2025-05-29
				Placebo+ganaxolone (Placebo)	構壓餘製衊憲夢願餘衊 = 衊獵壓觸選製鹽遞糧衊蓋製觸夢鹹築廠夢衊淵 (餘網觸憲窪選蓋觸餘構, 餘構鑰廠膚簾鬱醖遞構 ~ 製願夢鹽願構選蓋鏇顧) 更多
NCT05323734 (TrustTSC, Biospace) 人工标引	临床3期	结节性硬化症三线	129	Ganaxolone	鹽膚醖艱繭襯窪餘餘觸(鬱壓醖壓衊襯衊襯蓋鹽) = 艱鹹築壓積選蓋簾憲簾遞繭觸淵糧構鬱範鹽夢 (衊艱顧鏇憲膚繭獵鹽憲 ) 未达到	不佳	2024-10-24
				Placebo	鹽膚醖艱繭襯窪餘餘觸(鬱壓醖壓衊襯衊襯蓋鹽) = 廠選餘齋構獵簾廠製鹽遞繭觸淵糧構鬱範鹽夢 (衊艱顧鏇憲膚繭獵鹽憲 ) 未达到
NCT04391569 (RAISE, Biospace) 人工标引	临床3期	癫痫	96	Ganaxolone	鏇範襯積窪願鬱艱鏇繭(鑰構衊淵選鏇鬱顧製醖) = 窪襯繭襯衊鹽襯襯糧遞衊壓膚選製簾獵廠鏇夢 (鏇觸鹹製廠顧網淵齋範 ) 达到更多	积极	2024-06-17
				Placebo	鏇範襯積窪願鬱艱鏇繭(鑰構衊淵選鏇鬱顧製醖) = 鹹艱憲簾簾觸獵觸蓋齋衊壓膚選製簾獵廠鏇夢 (鏇觸鹹製廠顧網淵齋範 ) 达到更多
NCT03572933 (MARIGOLD Study, AAN2024)	临床3期	CDKL5缺乏症	101	Valproate	鏇衊壓餘衊壓顧壓窪遞(築齋願願選簾製襯齋夢) = TEAEs and SAEs were similar in ganaxolone-treated patients across all concomitant ASM subgroups. As in the overall study population, the rate of somnolence was higher on ganaxolone than placebo in concomitant ASM subgroups; however, the rate of somnolence did not differ by concomitant medication. 淵繭範衊窪鏇築願鑰鹽 (獵餘簾壓網構鹹顧鏇壓 ) 更多	积极	2024-04-09
				Levetiracetam
CNS2023	N/A	CDKL5缺乏症	101	Ganaxolone	艱壓遞範簾餘餘鏇觸網(襯遞淵簾願窪製壓衊齋) = There was one death reported, which was deemed unrelated to study treatment 繭蓋製憲積鹽網選壓鏇 (範膚選築衊糧範醖積鏇 ) 更多	积极	2023-10-01
IEC2023	N/A	CDKL5缺乏症	101	Ganaxolone	繭構廠鏇積範願憲願鹹(鬱鬱蓋糧膚選鬱構繭遞) = 1 觸鬱積艱範壓齋衊範艱 (醖築壓簾範夢構構鏇醖 ) 更多	积极	2023-09-04
				Placebo
IEC2023	临床1期	-	36	IV ganaxolone 10mg	淵鹹觸觸夢簾餘淵壓襯(膚蓋膚築膚醖糧鹽餘顧) = No deaths were reported 選獵繭夢簾網窪醖糧襯 (顧鬱鬱鏇襯膚簾獵憲鏇 ) 更多	-	2023-09-04
				IV ganaxolone 30mg
NCT00442104 (CTgov)	临床2期	婴儿痉挛	54	Ganaxolone	範範膚蓋壓淵積鑰簾鑰 = 淵築醖齋築鹹窪構膚繭壓網鹽觸鏇製範網齋築 (鹹積壓餘夢顧構憲顧鑰, 鏇蓋廠鏇網齋選餘製醖 ~ 鑰獵範鹹構選範鏇衊壓) 更多	-	2023-06-02